Esperion’s 2025 Close: Growth in U.S. Cradle, a Nasal-Spray Bet, and a Vision 2040 in Play

Ticker ESPR • EPS • earnings surprise • EPS consensus • revenue forecast • U.S. net product revenue

Overview: What ESPR Just Told the Street

Esperion Therapeutics, Inc. (ESPR) published its fourth-quarter and full-year 2025 results, paired with a strategic corporate maneuver that looks more like a plan than a one-off. The company leans into momentum in its bempedoic acid franchise, a successful year in U.S. commercial execution, and a bold step toward expansion via the proposed acquisition of Corstasis Therapeutics. The narrative isn’t just about numbers; it’s about positioning for a multi-product future and a long-term Vision 2040 that aspires beyond the usual quarterly cadence.

Financial highlights

Q4 2025 total revenue: $168.4 million, up 144% year over year.
Full-year 2025 total revenue: $403.1 million, up 21% year over year.
Q4 2025 U.S. net product revenue: $43.7 million, up about 38% year over year.
Full-year 2025 U.S. net product revenue: $159.6 million, up 38% year over year.
Commercial momentum: Strengthened payer coverage with NEXLETOL and NEXLIZET—now covering >90% of commercial lives and >90% of Medicare beneficiaries.

The press release emphasizes posted momentum in prescriptions and access, alongside a notable uplift in U.S. revenue that outpaced broader expectations for a late-stage cardiovascular program. What’s missing, for now, is a stated EPS figure or an explicit EPS consensus number in this excerpt. Investors will be parsing the next quarterly release for an explicit EPS trend and any earnings surprise signal relative to consensus estimates.

Commercial momentum and product slate

Esperion’s U.S. cardiovascular franchise continues to show resilience. The company highlights robust gains in prescription growth and market access, driven by stronger reimbursement. Notably, Enbumyst (bumetanide nasal spray) sits at the center of the strategic pivot—an asset positioned to accelerate growth and broaden cardiovascular and renal indications. The move aligns with Vision 2040’s multi-product, innovation-driven blueprint and underscores a willingness to blend organic growth with strategic M&A to accelerate near-term revenue capabilities.

On the operational front, Esperion reports increases in prescriber activity and access support, with Significant expansion in the number of unique healthcare providers prescribing NEXLETOL and NEXLIZET—from 36,311 to 44,991, a roughly 24% uptick in 2025. Q4 retail prescription equivalents rose about 34% year over year and 11.3% sequentially, signaling ongoing brand adoption and payer alignment.

Strategic acquisition: Corstasis Therapeutics

The proposed acquisition of Corstasis Therapeutics is framed as a catalyst to accelerate growth and expand Esperion’s cardiovascular franchise with Enbumyst. The deal is positioned as synergistic—leveraging Esperion’s commercial infrastructure to accelerate a nasal-spray diuretic portfolio that targets edema linked to CHF, hepatic disease, and renal disease. In capital markets terms, it’s a classic combination of product-market fit with a platform expansion that could meaningfully affect top-line trajectory and patient access dynamics.

Analysts will weigh the acquisition against integration risk, potential pricing and payer dynamics, and the timeline to scale Enbumyst as a revenue contributor that complements existing therapies. The press release also emphasizes alignment with Vision 2040, suggesting a deliberate strategy to diversify beyond a single-drug focus.

IP, settlements, and what it means for earnings visibility

Esperion notes settlements with five key ANDA filers, including Dr. Reddy’s, restricting generic entry until April 2040 and clearing some patent litigation challenges. Key patent expiries are cited as March 2036 and June 2040 for remaining patents. This IP backdrop is relevant to revenue forecast stability and to the earnings surprise risk profile that investors often weigh when evaluating pharma and biotech cash flows.

In short, the IP landscape offers some near-term protection but remains a variable for longer-term profitability. The upcoming earnings cadence will reveal how much these protections translate into multiple-year revenue visibility and whether the market gives the stock credit for the Corstasis move beyond the usual one-off approval wins.

What this could portend for ESPR and sector peers

The narrative here hinges on growth velocity, not just growth. If Corstasis integration accelerates Enbumyst adoption and payer coverage, Esperion could deepen its revenue ladder while dampening the volatility commonly associated with late-stage drug portfolios. The emphasis on revenue forecast durability matters as much as the headline revenue growth rate. The absence of a disclosed EPS figure in this release is conspicuous enough to warrant close attention to the next quarterly results for an explicit EPS consensus read and any earnings surprise delta.

For sector peers, a few themes emerge. First, the market rewards strategic bolt-ons that expand the addressable market with a credible commercialization plan. Second, payer dynamics and market access continue to be the gatekeepers of sustained revenue growth in cardiometabolic franchises. Third, robust IP protection—while not a guarantee—still matters for investor confidence in earnings stability, especially when a company relies on a portfolio of products rather than a single blockbuster.

Equity markets could respond to Esperion’s multi-product blueprint with a more differentiated view of risk: the stock may trade on execution clarity rather than pure science risk. If Vision 2040 translates into a credible path to durable, expanded gross margins and steady cash generation, sector peers might accelerate similar strategies—balancing internal pipelines with opportunistic acquisitions to defend against generic competition and pricing pressure.

Final thoughts

Esperion closes 2025 with a message: revenue growth is real, the U.S. commercial engine is humming, and a strategic acquisition could widen the runway. The EPS trajectory remains to be clearly defined in forthcoming reports, as does the precise earnings surprise trajectory versus EPS consensus. The company’s revenue forecast trajectory for 2026 will be the crucible for investor confidence in Vision 2040’s multi-product ambition.

For readers tracking ESPR and its peers, the core takeaway is this: growth is increasingly packaged as a platform play—one that depends on timely integration, durable access, and disciplined capital allocation. The nasal-spray anchor could become a case study in how a single asset, if scaled under a strong commercial framework, can shift a company’s growth character and the industry’s pricing and access dynamics.